Latest News and Press Releases

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.

GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administrationNext arms of study, including multiple ascending dose (MAD), underway and expected to complete...

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.

Neurogen Announces Partnership with NeuroX, a subsidiary of American TelePhysicians

Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.

Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.

Washington D.C., March 27, 2025 (GLOBE NEWSWIRE) -- International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain...

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.